NCT02044120 2021-01-12ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing SarcomaSarcoma Alliance for Research through CollaborationPhase 1 Completed34 enrolled